S.N. GADIYA & CO. Chartered Accountants 241, Apollo Tower, 2, M.G. Road, INDORE-452001 Ph : 4069030, 4031266 S.N. GADIYA B.Com. F.C.A LIMITED REVIEW REPORT FOR THE QUARTER ENDED ON 30°” JUNE 2014 We have reviewed the accompanying statement of unaudited financial results of MIS. BIOFIL CHEMICALS & PHARMACEUTICALS LTD (CIN (24233MP1985PLC002708) for the quarter ended 30" June 2074 except for the disclosures regarding ‘Public Shareholding’ and ‘Promoter and Promoter Group Shareholding’ which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibilty of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors, Our responsiblity is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which itis to be disclosed, or that it contains any material misstatement For S.N. Gadiya & Co. Chartered Accountants: (Registration No: 002052C) G4-->- Place: Indore (S.N.Gadiya ) Date : 14/08/2( Proprietor Membership No: 71229Un-Audited Financial Results of Quarter Ended Jun. 2014 ‘CIN NO. 124233MP1985PLC002709 30-06-2014 of Mis. Biofil Chemicals & Pharmaceuticals Limited 14/12, Sector-'E" Sanwer Road, Industrial Area, Indore (M.P.) Un-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2014 Rs. In acs PARTI Tis. in Lakhs) Particulars Tmonthe | EMonthe | Preceding 3 | Audited for quarter | quarter | months | the year ‘ended | ended | quarter | ended sorogr2014 | 31/03/2014 | ended | s1/osr2014 30/08/2013 (Refer Netes Below) Reviwed | (audited) | Reviwed | (Aualtod) “income from eperations (@) Net sales income rom operations (Net of Braise du) soos] 113.24 a7] 488.8 (©) Other operating neome S T1272 : 22828] Fatal income from operations (net) 5008] 225.87 wml 717.7 2 [Expenses (@)_Cost of materiale consumed 7323 73.88 sire 168:75 (6) Purchases of stockin-rede 720.90 106.21 2372] 308.10 (@) Changes inventories offiished goods, workin- progress and stock-in-trade 2.14 ess] 225] 18.17 (@ Employee benetits expense 6.32 24.62] 6304130) (©) Depreciation and amortisation expense 5c] e.l 525| 22.29 {Ger expansan(hny Tom exceeding 10% oF he (oad ‘expenses relating to continuing operations tobe shown separately) 7.68 10.85 871 gaa] Total expenses ssa] 162.48 was] 642.73 “| Profit (Loss) from operations bofore other Income, nance costs and exceptional items (1-2) (68a| 73.49 rar|__ 74a “]otner income 14.63] 2.89 +.05| 5.8 G|Profit/ (Loss) from ordinary activities before finance costs land exceptional items (3+ 4) a7 1632 ssz| 80.42 [Finance costs 3.75 4a 375 15.36 7 Profit (Loss) from ordinary activities after finance costs But lpefore exceptional items (5 + 6) 5.04 rat 457| 65.06 B]Exceptional tems me 4.00 41.00 9) Profit 7 (Loss) from ordin i xe Cee jenrontdon before ex G86) 5.08 na 4s7| 64.06 *o) Fax expanse 12.40 12.40 Ti] Net Prof (Loss) from ordinary activites after tax (@ = 10) (tess) ” adh 5.04 58.84 4s7| 54.68 "a|Minoniy wtereat™ 73]fiot profil fioes) afer taxes minoriy Interest and ehare of rofl (loss) of associates pee Cet) lan iants) 5.08 58.81 4s7| 51.68 7 Paid-up equiy share capital 177.38] 162738 1627-38] 1627.38 [Face Value of he Share shal bo dicated) 10] Ft 10 a0 7 |Reserve exchiding Revaluation Reserves -1220.02 FSi [Earnings per share before extraordinary Rema) {oFRe. 107 each) (not annwaioe 0.0031] 0.361] 0.0028] __ 0.0317)WW si PART Ww sccompanying note to the financial results Smonths ‘quarter ended 30/06/2014 ‘Months quarter ended 3103/2014 Preceding 3 | Audited for ‘months | the year quarter | ended ended | 31/03/2014 30/06/2013, PARTICULARS OF SHAREHOLDING Public shareholding 8655100] 8655100] = Number of shares = Percentage of shareholding 53.16 53.19] Promoters and Promoter Group Shareholding ** 1) Pledged / Encumbered = Number of shares «Percentage of shares (as a % of the total shareholding of promoter and promoter soup) = Percentage of shares (as a % of the total share capital of the company) ) Non- encumbered = Number of shares. = Percentage of shares (as a % of the otal shareholding of| the Promoter and Promoter rou) «= Percentage of shares (as a % ofthe total share capital of| the company) Is investor COMPLAINTS JPending at the beginning ofthe querter Nil Received during the quarter 1 Disposed of uring the quarter 1 [Remaining unresolved atthe end ofthe quarter Nt 1. Above Unaudited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their meeting held on 14th August 2014 2. Figures have been regrouped wherever necessary including as per revised schedule VI 3. The Statuary auditors have carried out a limited review of the resi quarter ended 30th June 2014 Date: 14.08.2014 Place: Indore < {DIN NO. 00326110)BIOFIL CHEMICALS & PHARMACEUTICALS LTD. CIN NO. L24233MP1985PLC002709 ‘Segmentwise Revenue, Results an Capital Employed for Quarter ended 30th June 2014 (Under Clause 41 Lsting Agreement) Rs. Inlacs [SNo__|Segmont Revenue Quarter Ended ‘June 30, March 31, [June 30, [34 March 2014 2014 2013 [2014 Reviewed ‘Audited | Reviewed | Audited i|Segment Revenue Pharma Unit 2723] 20169, 7646 | __545.97 [Chemicals Division 14.60] 62.99 56.37 | 14465 [Plastic Division 3.22] 0.54 14.90 26.54 [Other 4463 3.34 1.05 64s [Gross Turnover e468 268.56 38.80| 723.68 2|Segment Results [Pharma Unit 15.28 8375 (125)| 158.29 [Chemicals Division (3.07) (78.94) 11.82 (72.58)| Plastic Division (3.49) (29.94) (2.25)| 752) [Other 0.00 007 0.00 112 [Total Segment Profit Before Tax B78 (25.08) 32 79.31 interest Income 0.00 043 0.00 043 Interest Expenses 3.75) 3.82 3.75 15.07 [Other Unallocable Income nat of Expenditure Profit Before Tax 504 (2.485) 457 6467 Provision for current tax 0.00 12.32 = 12:32 1.00) Profit After Tax 508 (wom 457 EE 3|Capital Employed [(Segment Assets- Segment Liabilities) [Pharma Unit a1 737.25 a0] 13725 [Chemicals Division 732.08 689.52 732.09 | 689.52 [Plastic Division (9.55) (52.88)| (39.55)| (62.88) [Other (3.86)| - (3.86) = [Total Capital Employed 734.69 77390| 734.88 | 773.90 DATE : 14-08-2014 PLACE: INDORE peg BOF CHEBIOFIL CHEMICALS & PHARMACEUTICALS Ltd. UN-AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30-06-2014 CCIN NO. L24233MP1985PLC002709 (in Rs.) ‘Standalone / Consolidated Statement of Assets and As At As at Liabilities (Current year end] | (Current year end) Particulars 30-06-2074 31-03-2014 x [EQUITY & LIABILITIES 7 | Shareholders’ funds (@) Share Capital TezTSB000| 7762738000] (b) Reserves & Surplus (3604785) 784108795)] (9 Money received against share warrants ‘Sub-total - Shareholders funds} 7a1ss205] 7a629205| [Share application money pending allotment [Minority interest = (@) Long-orm borrowings (6) Deferred tax abilities (pet) (€) Other long-term labilties (@) Long-term provisions ‘Sub-total_Non-current labiities 3[Corrent rabies (a) Short-term borrowings PESTO e705 (b) Trade payables '35027896| 36357692 (@) Other current iabiiies 5 zi (g) Short term provisions. 537535] a ‘Subtotal Current Nabiitieg| 32658003] 7357471 TOTAL — EQUITY AND LIABILITIES| ESEIPEH) TaSSEESTS| iE [ASSESTS. 7 |Non-current assets (a) Fixed assois Tangible Assess BHITeBsA STS TH) Goodwill on consoldation (¢) Non-current investments () Deferred tax assets (not) (e) Long-term loans and advances. ‘Other non-current assets ‘Sub-total - Non-current assets) Ti76634] orra7634 2\Gurent assets [Current investments lnventories 760023] 2735670) Trade receivables 72590844] i041 103) [Cash and cash equivalents 668104] 1732875) [Short-term loans and advances, 4970004] 3153148] [Other current assels 2501620] 2531139] ‘SubTotal - Current assets) Ean BaBEADAD| — TOTAL - ASSETS) TaS7OTIOG] TAEDEESTE| DATE : 14-08-2014 PLACE: INDORE